scholarly journals In vivo paracrine effects of ATP-induced urothelial acetylcholine in the rat urinary bladder

2020 ◽  
Vol 227 ◽  
pp. 102689
Author(s):  
Johanna Stenqvist ◽  
Patrik Aronsson ◽  
Thomas Carlsson ◽  
Michael Winder ◽  
Gunnar Tobin
2005 ◽  
Vol 33 (5) ◽  
pp. 552-560 ◽  
Author(s):  
Martin B. Oleksiewicz ◽  
Inger Thorup ◽  
Henriette S. Nielsen ◽  
Hanne V. Andersen ◽  
Anne Charlotte Hegelund ◽  
...  

PPAR Research ◽  
2008 ◽  
Vol 2008 ◽  
pp. 1-14 ◽  
Author(s):  
Martin B. Oleksiewicz ◽  
Jennifer Southgate ◽  
Lars Iversen ◽  
Frederikke L. Egerod

Despite clinical promise, dual-acting activators of PPARαandγ(here termed PPARα+γagonists) have experienced high attrition rates in preclinical and early clinical development, due to toxicity. In some cases, discontinuation was due to carcinogenic effect in the rat urothelium, the epithelial layer lining the urinary bladder, ureters, and kidney pelvis. Chronic pharmacological activation of PPARαis invariably associated with cancer in rats and mice. Chronic pharmacological activation of PPARγcan in some cases also cause cancer in rats and mice. Urothelial cells coexpress PPARαas well as PPARγ, making it plausible that the urothelial carcinogenicity of PPARα+γagonists may be caused by receptor-mediated effects (exaggerated pharmacology). Based on previously published mode of action data for the PPARα+γagonist ragaglitazar, and the available literature about the role of PPARαandγin rodent carcinogenesis, we propose a mode of action hypothesis for the carcinogenic effect of PPARα+γagonists in the rat urothelium, which combines receptor-mediated and off-target cytotoxic effects. The proposed mode of action hypothesis is being explored in our laboratories, towards understanding the human relevance of the rat cancer findings, and developing rapid in vitro or short-term in vivo screening approaches to faciliate development of new dual-acting PPAR agonist compounds.


1980 ◽  
Vol 58 (5) ◽  
pp. 536-542 ◽  
Author(s):  
F. Marceau ◽  
J. Barabé ◽  
S. St-Pierre ◽  
D. Regoli

The contractile response of the rat isolated urinary bladder to kinins is mediated by receptors of the B1 and of the B2 types, as this preparation responds to des-Arg9-bradykinin (des-Arg9-BK), a fairly selective stimulant of receptor B1 and to [Tyr(Me)8]-BK, a potent agonist on receptor B2. Des-Arg10-[Leu9]-kallidin, a specific and competitive antagonist of the action of kinins on receptor B1, has been found to block the effect of des-Arg9-BK in concentrations similar to those required in the rabbit aorta; therefore, the B1 receptor of the rat urinary bladder is analogous to that of the rabbit vascular tissue.The response of the rat urinary bladder to des-Arg9-BK increases progressively from near null level during the incubation in vitro and can be abolished by cycloheximide; this suggests that receptor B1 of the rat urinary bladder is formed de novo.The inflammation of the bladder induced by intravesical injection of the detergent Triton X-100 enhances the initial response to des-Arg9-BK without modifying the response to other agents. The B1 receptor is formed in vivo in the rat urinary bladder submitted to the Triton X-100 treatment but not in the control untreated organ. The local de novo synthesis of B1 receptors for kinins that follows a noxious stimulus is proposed as a possible mechanism implicated in the chemical mediation of the inflammatory process.


1999 ◽  
Vol 80 (1-2) ◽  
pp. 41-47 ◽  
Author(s):  
Alessandro Lecci ◽  
Stefania Meini ◽  
Manuela Tramontana ◽  
Sandro Giuliani ◽  
Marco Criscuoli ◽  
...  

1995 ◽  
Author(s):  
Bernard Lobel ◽  
Ophir Eyal ◽  
Edward Belotserkovsky ◽  
Ofer Shenfeld ◽  
Noam Kariv ◽  
...  

2000 ◽  
Vol 389 (1) ◽  
pp. 99-102 ◽  
Author(s):  
Alessandro Lecci ◽  
Sandro Giuliani ◽  
Manuela Tramontana ◽  
Stefania Meini ◽  
Paolo Santicioli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document